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Abstract
Introduction Spontaneous resorption of disc herniation (DH)
after sciatica is well documented. The matrix metalloproteinases
(MMP)-1 and MMP-3 are enzymes potentially involved in this
process. Glucocorticoid injections are commonly used for
treatment, and other anti-inflammatory molecules like tumor
necrosis factor (TNF) inhibitors are under clinical investigation.
However, little is known about the effect of these molecules on
DH resorption.
Methods DH tissue was harvested from patients undergoing
surgery for sciatica. Samples were thoroughly washed. Diced
explants were cultured ex-vivo in 1) 0.5 ml Dulbecco's modified
Eagle's medium (DMEM) 10% fetal calf serum (FCS), (controls),
2) recombinant interleukin 1 receptor antagonist (IL-1Ra), (100
ng/ml), 3) dexamethasone (10E-5 M), or 4) TNF inhibitor
monoclonal antibody (10 μg/ml). Supernatants were harvested
at 48 hours and frozen. Immunocapture activity assays
determined total MMP activity, active MMP levels and pro-MMP
levels.
Results Fourteen DH tissue samples were analysed. Levels of
all forms of MMP-3 were higher than the respective levels of
MMP-1(P < 0.01). In particular, the median (interquartile range
[IQR]) total MMP-3 level was 0.97 (0.47 - 2.19) ng/mg of tissue
compared to 0.024 (0.01 - 0.07) ng/mg of total MMP-1 level (P
< 0.01). Incubation with IL-1Ra, dexamethasone, or TNF
inhibitors significantly decreased levels of all forms of MMP-3 (P
< 0.05). Dexamethasone significantly decreased the ratio of
active MMP-3 to total MMP-3 activity. A significant inhibitory
effect of dexamethasone was observed only on active MMP-1,
while IL-1 and TNF inhibitor had no significant effect on any
form.
Conclusions MMP-3 appears to play a greater role than MMP-
1 in DH resorption. Dexamethasone, IL-1-Ra and TNF inhibitor
decreased active MMP-3, indicating that the clinical use of
these drugs may affect the resorption of DH under certain
conditions.
Introduction
Disc herniation (DH) is classically described as the protrusion
of degenerated disc tissue within the spinal canal [1].
Although DH is found in many asymptomatic subjects, lumbar
DH is associated with radicular leg pain syndrome often
referred to as sciatica. While sciatica was long thought to
result only from mechanical compression of the nerve root,
recent studies have underlined the importance of inflammation
and cytokines in this process. Partly for this reason, glucocor-
ticoids [2] and, more recently, TNFα inhibitors [3,4] were intro-
duced in the treatment of sciatica. The usual clinical evolution
of sciatica is toward recovery with resolution of leg pain.
Reduction in clinical symptoms has been shown to be corre-
lated with a reduction of DH size on subsequent magnetic res-
onance imaging [5].
Matrix metalloproteinases (MMPs) are a group of over 20 zinc-
dependent enzymes that catalyze the degradation of protein
components of the extracellular matrix. MMPs therefore con-
tribute to the tissue resorption and remodeling of the extracel-
lular matrix that occur in reaction to tissue degeneration [6].
MMP-1 (collagease-1) and MMP-3 (stromelysin-1) are known
to be involved in the turnover of normal tissue but also in its
pathological degradation. Osteoarthritis [7,8], spondyloar-
thropathy [9] or intervertebral disc (IVD) degeneration [10]
illustrates this process. MMPs have also been shown to be
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increased in DH tissue compared with that of healthy IVDs
[11] and participate in DH degradation and resorption after an
episode of sciatica [12]. Little information is available, how-
ever, on their respective importance in this process.
Synthesized as inactive pro-zymogens, MMPs go through a
post-transcriptional process of cleavage and activation, ena-
bling the targeted degradation of their substrate. The regula-
tion of MMP activity is a complex and finely tuned process in
which both specific inhibitors (tissue inhibitors of metallopro-
teinases) and the regulation of afferent pathways at production
and activation levels play an important part. Inflammatory
cytokines such as IL-1 and TNFα are thought to contribute to
these regulatory processes [7]. The use of glucocorticoids [2]
and TNF inhibitors [3,4] in the treatment of sciatica might
therefore hinder DH resorption and, possibly, the median or
long-term evolution of the disease.
The goal of the present study was therefore to investigate the
effects of glucocortiocoids (dexamethasone) and specific
cytokine inhibitors (IL-1Ra and anti-TNF antibody) on levels of
MMP-1 and MMP-3 in DH. We used assays that distinguish
active enzymes from inactive enzymes to partially address the
level of regulation at which these drugs might be active.
Materials and methods
The local research ethics committee's approval was given for
the work. DH tissues were obtained after informed consent
from 14 patients undergoing surgical lumbar discectomy for
persistent radicular symptoms. No patients had received glu-
cocortiocoids within 2 weeks prior to surgery and none had
received IL-1 or TNF inhibitors at any time.
Freshly obtained tissue samples were immediately transported
in a dry environment to the laboratory, thoroughly washed with
DMEM in order to remove any blood contamination, and diced
into pieces of approximately 50 mg. The time duration
between sample collection and processing did not exceed 1
hour. Histological analysis was performed on the first two DH
samples. All samples were subsequently incubated ex vivo at
37°C for 48 hours either in 0.5 ml DMEM supplemented with
10% FCS, in penicillin and streptomycin alone (controls), or
with the addition of dexamethasone (10-5 M), IL-1 Ra (100 ng/
ml; R&D Systems Europe Ltd, Abingdon, Oxfordshire, UK) or
anti-TNFα monoclonal antibodies (10 ng/ml; R&D Systems
Europe Ltd). Concentrations of anti-inflammatory molecules
were chosen to match those reached in tissue in vivo after sys-
temic administration. All tissue samples were incubated in
duplicate. At the end of the incubation period, supernatants
were harvested, aliquoted and stored at -80°C until assays
were performed.
Immunocapture activity assays
MMP-1 and MMP-3 activity assays (Amersham Biosciences,
Little Chalfont, Buckinghamshire, UK) were performed accord-
ing to the recommendations of the supplier. These assays
measure spontaneous MMP activity (active MMP) and total
MMP activity after activation (total MMP activity = spontane-
ously active + activatable pro-MMP; Figure 1), but do not cap-
ture MMP-proteinase inhibitor complexes (inactivated MMP).
Total MMP, frequently referring to the sum of all three forms
(pro-MMP, active MMP and inactivated MMP) because the
usual immunoassays capture indistinctly all three forms at the
same time, was not measured in the present study.
In the activity assay used in this study, MMP-1 or MMP-3 is
captured by a specific antibody that has been immobilized on
a microtiter plate. The amount of active MMP is measured
directly by the incubation of the captured MMP with modified
pro-urokinase (Ukcol, Amersham Biosciences), and subse-
quently activated Ukcol is quantified by a chromogenic sub-
strate (S-2444, Amersham Biosciences). Color development
is recorded at 405 nm at different time intervals. Total MMP
activity (in the present study, the pro-MMP plus active MMP)
is assessed through the activation of pro-MMP by preincuba-
tion with 0.5 mmol/l p-aminophenylmercuric acetate for 2
hours at 37°C before the addition of modified Ukcol and chro-
mogenic substrate.
The level of pro-MMP can be computed by subtracting active
MMP from total MMP activity (Figure 1). Activity is expressed
in recombinant enzyme equivalents in nanograms per milliliter.
The lower detection limits were 1.7 ng/ml recombinant enzyme
equivalents for MMP-1 and 3.75 ng/ml recombinant enzyme
equivalents for MMP-3. Results were adjusted for the dry
Figure 1
Different forms of matrix metalloproteinase enzymes and their usual  nomenclature Different forms of matrix metalloproteinase enzymes and their usual 
nomenclature. Immunocapture activity assays (used in the present 
study) detect both total matrix metalloproteinase (MMP) activity and 
active MMP, while the standard ELISA method detects total MMP 
(inactive, active and inactivated forms). TIMP, tissue inhibitor of matrix 
metalloproteinase.Available online http://arthritis-research.com/content/11/6/R169
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weight of each sample and are presented as nanograms per
milligrams (ng/mg) of tissue.
Statistical analysis
As results were not normally distributed, they are presented as
median (interquartile range (IQR)), displaying the first (25%)
and the third (75%) quartiles. A nonparametric Wilcoxon
signed rank sum test was used to compare the levels of each
MMP after incubation with, respectively, IL-1Ra, dexametha-
sone, or TNF inhibitor with the levels of MMPs measured in the
control samples. All tests were conducted at an alpha level of
error of 0.05. Calculations were performed with STATA v. 9.2
for Windows (StataCorp LP, College Station TX, USA).
Results
DH tissue was collected during surgery from 14 patients
(Table 1) operated for DH and sciatica unresponsive to con-
ventional conservative treatment. Most patients had a history
of chronic back pain prior to the acute episode of leg pain; two
patients had already suffered from a previous episode of radic-
ulopathy. None of them had had prior back surgery. Leg pain
duration ranged from 3 to 200 weeks at the time of surgery. All
patients had a positive straight leg raise sign or radicular irrita-
tion sign and/or a definite neurological deficit. Seven of them
had a combination of two or three neurological signs. Accord-
ing to visual examination by the surgeons during surgery, 11
DH samples were subligamentous and three DH samples had
crossed the posterior ligament.
Basal matrix metalloproteinase levels
Levels of active MMP-1 and total MMP-1 activity were ana-
lyzed in 13 DH samples. The median (IQR) level of total MMP-
1 activity was 0.024 (0.01 to 0.07) ng/mg tissue and was
0.006 (0 to 0.03) ng/mg tissue for active MMP-1. The median
(IQR) level of pro-MMP-1 was 0.01 (0.06 to 0.04) ng/mg tis-
sue.
Levels of active and total MMP-3 activity were analyzed in 13
DH samples, 11 of them being the same tissue as that used
for MMP-1 level determination. The median (IQR) level for total
MMP-3 activity was 0.97 (0.47 to 2.19) ng/mg tissue and was
0.25 (0.17 to 0.75) ng/mg tissue for active MMP-3. The
median (IQR) level of pro-MMP-3 was 0.47 (0.19 to 1.34) ng/
mg tissue.
The median levels of total MMP-3 activity, active MMP-3 and
pro-MMP-3 were found to be more than 30 times higher than
those of the respective forms of MMP-1, P < 0.01 (Figure 2).
None of the clinical characteristics as displayed in Table 1,
such as duration of leg pain before surgery or the extension of
DH beyond the posterior ligament, were significantly corre-
lated with any of the MMP-1 or MMP-3 levels.
Effect of inhibitors on matrix metalloproteinases
Incubation with dexamethasone significantly decreased the
concentrations of total MMP-1 activity from 0.03 (0.01 to
0.07) ng/mg tissue to 0.004 (0.003 to 0.017) ng/mg tissue, P
= 0.04, and of active MMP-1 from 0.007 (0.0007 to 0.03) ng/
mg tissue to 0.001 (0.0003 to 0.003) ng/mg tissue, P = 0.03.
Dexamethasone did not, however, affect the concentration of
pro-MMP-1. Incubation with IL-1Ra, which could be analyzed
in only eight samples, or with TNF inhibitor did not affect the
concentration of any forms of MMP-1 (Figure 3). Addition of
the anti-inflammatory drugs did not significantly modify the
ratio of active MMP-1 to total MMP-1 activity.
Incubation with dexamethasone significantly decreased the
concentrations of all forms of MMP-3. The total MMP-3 activity
level went down from 0.9 (0.4 to 2.26) ng/mg tissue to 0.46
(0.25 to 0.91) ng/mg tissue, P = 0.01, that of active MMP-3
from 0.25 (0.17 to 0.87) ng/mg tissue to 0.09 (0.05 to 0.19)
ng/mg tissue, P = 0.02, and that of computed pro-MMP-3
from 0.47 (0.19 to 1.34) ng/mg tissue to 0.39 (0.16 to 0.72)
ng/mg tissue, P = 0.04 (Figure 4).
Incubation with IL-1Ra significantly decreased the concentra-
tions of all forms of MMP-3. The total MMP-3 activity level went
down to 0.35 (0.21 to 0.7) ng/mg tissue, P < 0.01, that of
Table 1
Baseline characteristics of the patients
Disc herniation samples
Sample size 14
Age (years) 45 (15)
Gender (% male) 45
Leg pain duration (weeks) 14 (10 to 40)
Type of back pain
Acute 5
Chronic 10
Type of leg pain
First episode 13
Previous episodes 2
Positive nerve root irritation signa 14
Neurological deficit
Muscle weakness 8
Sensory perturbation in a dermatome 9
Decrease deep tendon reflex 5
Disc level
L3 to L4 2
L4 to L5 7
L5 to S1 6
Data presented as n, mean (standard deviation) or median 
(interquartile range). aStraight leg-raising or femoral stretch.Arthritis Research & Therapy    Vol 11 No 6    Genevay et al.
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active MMP-3 to 0.07 (0.06 to 0.15) ng/mg tissue, P < 0.01,
and that of computed pro-MMP-3 to 0.29 (0.13 to 0.59) ng/
mg tissue, P = 0.02 (Figure 4).
Incubation with TNF inhibitor significantly decreased the con-
centration of total MMP-3 activity to 0.3 (0.22 to 0.88) ng/mg
tissue, P = 0.01, and that of active MMP-3 to 0.13 (0.53 to
0.21) ng/mg tissue, P = 0.03. There was a nonsignificant
decrease in the level of pro-MMP-3 to 0.2 (0.12 to 0.66) ng/
mg tissue, P = 0.06 (Figure 4).
The addition of dexamethasone decreased the ratio of active
MMP-3 to Total MMP-3 activity from 39% (25.6 to 53.9%) to
20.1% (16.0 to 25.0%), P = 0.02, whereas no significant dif-
ference was observed with IL-1Ra and TNF inhibitor.
Discussion
In the present study, all measured forms of MMP-3 were found
at higher concentrations than the corresponding forms of
MMP-1, suggesting that MMP-3 plays a greater role in DH
degradation than MMP-1. Our results inform on the process of
DH resorption, given the known specificities of these MMPs.
MMP-1 alone degrades native intact interstitial collagen mole-
cules. MMP-3 mainly contributes to the degradation of many
noncollagenous proteins, but it also breaks down previously
denatured collagen fibrils [10]. The presence of both enzymes
in DH tissue was previously reported [13], as was the effect of
MMP-3 on DH resorption [14]. These studies, however, did
not provide any information on the respective importance of
MMP-1 and MMP-3 in this process. In IVD tissue, MMP-1 is
expressed at a higher level than MMP-3 [12,15]. The propor-
tion of MMP-1 decreases with advancing disc degeneration,
and both enzymes are equally expressed in the most degener-
ative IVD [15]. Our results suggest that DH tissue resorption
may be even more dependent on MMP-3 than end-stage
degenerative IVD tissue. Further comparison with our study is
difficult as no IVD studies reported any information on MMP
levels or activity.
Each of the three drugs studied had a different effect on MMP-
1 and MMP-3 concentrations. IL-1Ra and TNF inhibitor only
affected MMP-3 levels, whereas dexamethasone was effective
in decreasing concentrations of both MMP-1 and MMP-3. To
the best of our knowledge, this study is the first to report a
direct effect (that is, without prior in vitro cell activation) of
either IL-1Ra, TNF inhibitors or dexamethasone on the levels
of MMP-1 and MMP-3 in DH tissue. Moreover, the anti-inflam-
matory agents' impact was observed in active components of
both MMP-1 and MMP-3, suggesting that using these drugs
could, at least under certain conditions, alter the speed and
extent of DH resorption after an episode of sciatica. Such an
effect was not reported after one foraminal injection of methyl-
prednisolone in patients with sciatica [16], but was observed
in a rabbit model using higher dosages [17]. Regarding TNF
inhibitors, a single infusion of infliximab [18] showed no effect
on DH resorption at 6-month follow-up, although resorption
was observed to slow down during the first 2 weeks post infu-
sion, compared with patients having received a placebo. This
time lag coincides with the 10 days serum half-life of the drug,
suggesting that repetitive infusion might affect disc resorption.
IL-1 Ra, but not TNF inhibitors, was recently reported to inhibit
matrix degradation in IVD [19]. This result differs both from our
findings and from a report of decreased serum levels of MMP-
3 in patients with spondyloarthropathy treated with TNF inhib-
itors [20]. A difference in tissue extracellular matrixcomposi-
tion between healthy IVD and DH tissue might account for this
discrepancy. Alternatively, the immunocapture activity assay
that was used in the present study specifically addresses each
form of the enzyme, whereas the zymography used for the
study on IVD assesses a global effect on substrate and pre-
cludes any conclusions for a specific enzyme [21]. As for dex-
Figure 2
Levels of matrix metalloproteinase-3 and matrix metalloproteinase-1 Levels of matrix metalloproteinase-3 and matrix metalloproteinase-1. Total matrix metalloproteinase (MMP)-3 activity and active MMP-3 levels were 
found at significantly higher levels than their respective MMP-1 form, *P < 0.01. Line in center of box, median; lower and upper borders of boxes, 
lower (Q1) and upper (Q3) quartiles; whiskers, minimum and maximum values; o, outliers (values exceeding 1.5 × (Q3 - Q1)).Available online http://arthritis-research.com/content/11/6/R169
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amethasone, no data on DH or IVD tissue are available. The
inhibitory effect on MMP-3 levels, however, has been reported
in chondrocytes [22] and in the serum level in rheumatoid
arthritis patients after intra-articular injection of glucocorti-
coids [23].
Many mechanisms are involved in the regulation of active MMP
levels: gene activation and repression, post-translational
acetylation, DNA methylation, post-transcriptional modification
of pro-MMP with complex activation of zymogens by free radi-
cals and other enzymes, and inhibition of active MMPs by
numerous molecules, including α2-macroglobulin and tissue
inhibitors of metalloproteinases. The present study was not
designed to investigate these different mechanisms. The
immunocapture activity assay, however, enabled the assess-
ment of the different forms of MMPs and permits some prelim-
inary observations. The inhibitory effect of dexamethasone on
active MMP-1, without modifying the ratio between active
MMP-1 and total MMP-1 activity, rather suggests an increase
in inhibitory molecules. Indeed, such an effect of dexametha-
sone has been reported on tissue inhibitor of metalloprotein-
ase-1 [24]. The impact of dexamethasone on pro-MMP-3
suggests an upstream effect on the pathways implicated in the
synthesis of this enzyme. Because of the additional effect
observed on the ratio of active MMP-3 to total MMP-3 activity,
however, a more complex effect on pathways of MMP-3 regu-
Figure 3
Effect of IL-1Ra, dexamethasone and TNF inhibitor on matrix metallo- proteinase-1 Effect of IL-1Ra, dexamethasone and TNF inhibitor on matrix metallo-
proteinase-1. Dexamethasone significantly inhibits both (a) total matrix 
metalloproteinase (MMP)-1 activity and (b) active MMP-1 without mod-
ifying levels of (c) pro-MMP-1. No effect was observed for IL-1Ra and 
TNF inhibitor. Line in center box, median; lower and upper borders of 
boxes, lower (Q1) and upper (Q3) quartiles; whiskers, minimum and 
maximum values; o, outliers (values exceeding 1.5 × (Q3 - Q1)).
Figure 4
Effect of IL-1Ra, dexamethasone and TNF inhibitor on matrix metallo- proteinase-3 Effect of IL-1Ra, dexamethasone and TNF inhibitor on matrix metallo-
proteinase-3. All three inhibitors decreased levels of (a) total matrix 
metalloproteinase (MMP)-3 activity and (b) active MMP-3 without mod-
ifying levels of (c) pro-MMP-3. Line in center of box, median; lower and 
upper borders of boxes, lower (Q1) and upper (Q3) quartiles; whiskers, 
minimum and maximum values; o, outliers (values exceeding 1.5 × (Q3 
- Q1)).Arthritis Research & Therapy    Vol 11 No 6    Genevay et al.
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lation may be postulated. Further work is certainly needed to
clarify these aspects.
The present study presents other limitations. First, the complex
process of extracellular matrix regulation involves other, possi-
bly yet unknown, enzymes in addition to MMP-1 and MMP-3.
As DH tissue has not been studied in as much detail as degen-
erative IVD tissue, we chose to focus on what are thought to
be two major MMPs, to the exclusion of less well-known mol-
ecules. Now that the results of the present study suggest that
the metabolism of DH tissue is somewhat different from that of
IVD tissue, further research is needed.
Second, for technical reasons, DH tissues had to be incu-
bated for 48 hours, in contrast to in vivo conditions, where the
effects of dexamethasone and cytokine inhibitors might be
quantitatively different. We do not, however, expect this to
affect qualitatively our conclusions.
The third limitation is that the in vitro conditions and the added
inhibitors might also have affected cell viability. The active syn-
thesis of MMPs in vitro speaks against large cell death, how-
ever, and the concentrations of anti-inflammatory molecules
were chosen to match those reached in tissues in vivo after
systemic administration.
The duration of symptoms prior to surgery varied widely and
could have lead to differences in the DH environment. Never-
theless, statistical analysis showed that duration of symptoms
was not correlated with any of the MMPs levels.
Finally, magnetic resonance imaging studies have demon-
strated that the speed and degree of DH resorption after an
episode of sciatica are related to the extension of DH in rela-
tion to the posterior longitudinal ligament, with transligamen-
tous DH tending to shrink faster. This may be due to the
quantity of granulation tissue present around the DH. In the
present study, unfortunately, only three samples of transliga-
mentous DH were available, which precludes any definitive
conclusion on this topic.
Conclusions
MMP-3 is present at higher levels than MMP-1 in DH, suggest-
ing it plays a predominant role in DH resorption. The effect of
dexamethasone and TNF inhibitors on the active forms of
MMP3 suggests that, at least under certain circumstances,
the clinical use of these drugs may affect the resorption of DH.
These results indicate in particular that further research on the
medium and long-term evolution of DH size and resorption
after TNF inhibitor treatment or glucocorticoid treatment is
warranted.
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